<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="abstract" xml:lang="en"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Cancer Imaging</journal-id><journal-id journal-id-type="iso-abbrev">Cancer Imaging</journal-id><journal-title-group><journal-title>Cancer Imaging</journal-title></journal-title-group><issn pub-type="ppub">1740-5025</issn><issn pub-type="epub">1470-7330</issn><publisher><publisher-name>BioMed Central</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmc">4242781</article-id><article-id pub-id-type="publisher-id">1470-7330-14-S1-S3</article-id><article-id pub-id-type="doi">10.1186/1470-7330-14-S1-S3</article-id><article-categories><subj-group subj-group-type="heading"><subject>Scientific Session Presentation</subject></subj-group></article-categories><title-group><article-title>Localised prostate cancer treated with MRI-guided transurethral ultrasound ablation: phase I trial results</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes" id="A1"><name><surname>Wolf</surname><given-names>MB</given-names></name><xref ref-type="aff" rid="I1">1</xref><email>m.mueller-wolf@dkfz.de</email></contrib><contrib contrib-type="author" id="A2"><name><surname>Roethke</surname><given-names>M</given-names></name><xref ref-type="aff" rid="I1">1</xref></contrib><contrib contrib-type="author" id="A3"><name><surname>Pahernik</surname><given-names>S</given-names></name><xref ref-type="aff" rid="I2">2</xref></contrib><contrib contrib-type="author" id="A4"><name><surname>Hadaschik</surname><given-names>B</given-names></name><xref ref-type="aff" rid="I2">2</xref></contrib><contrib contrib-type="author" id="A5"><name><surname>Kuru</surname><given-names>T</given-names></name><xref ref-type="aff" rid="I2">2</xref></contrib><contrib contrib-type="author" id="A6"><name><surname>Popeneciu</surname><given-names>IV</given-names></name><xref ref-type="aff" rid="I2">2</xref></contrib><contrib contrib-type="author" id="A7"><name><surname>Hatiboglu</surname><given-names>G</given-names></name><xref ref-type="aff" rid="I2">2</xref></contrib><contrib contrib-type="author" id="A8"><name><surname>Chin</surname><given-names>J</given-names></name><xref ref-type="aff" rid="I3">3</xref></contrib><contrib contrib-type="author" id="A9"><name><surname>Billia</surname><given-names>M</given-names></name><xref ref-type="aff" rid="I3">3</xref></contrib><contrib contrib-type="author" id="A10"><name><surname>Relle</surname><given-names>J</given-names></name><xref ref-type="aff" rid="I4">4</xref></contrib><contrib contrib-type="author" id="A11"><name><surname>Hafron</surname><given-names>J</given-names></name><xref ref-type="aff" rid="I4">4</xref></contrib><contrib contrib-type="author" id="A12"><name><surname>Nandalur</surname><given-names>K</given-names></name><xref ref-type="aff" rid="I4">4</xref></contrib><contrib contrib-type="author" id="A13"><name><surname>Burtnyk</surname><given-names>M</given-names></name><xref ref-type="aff" rid="I5">5</xref></contrib><contrib contrib-type="author" id="A14"><name><surname>Schlemmer</surname><given-names>HP</given-names></name><xref ref-type="aff" rid="I1">1</xref></contrib></contrib-group><aff id="I1"><label>1</label>Radiology, German Cancer Research Center (DKFZ), Heidelberg, Germany</aff><aff id="I2"><label>2</label>Urology, University Hospital, Heidelberg, Germany</aff><aff id="I3"><label>3</label>Urology, Western University (UWO), London Health Sciences Center, Victoria Hospital, London ON, Canada</aff><aff id="I4"><label>4</label>Urology and Radiology, Beaumont Health System, Royal Oak MI, USA</aff><aff id="I5"><label>5</label>Profound Medical Inc., Toronto ON, Canada</aff><pub-date pub-type="collection"><year>2014</year></pub-date><pub-date pub-type="epub"><day>9</day><month>10</month><year>2014</year></pub-date><volume>14</volume><issue>Suppl 1</issue><supplement><named-content content-type="supplement-title">Proceedings of the International Cancer Imaging Society (ICIS) 14th Annual Teaching Course</named-content><named-content content-type="supplement-sponsor">Publication charges for this supplement were funded through the International Cancer Imaging Society by support received from Siemens AG, Healthcare Sector, Imaging and Therapy Division.</named-content></supplement><fpage>S3</fpage><lpage>S3</lpage><permissions><copyright-statement>Copyright &#x000a9; 2014 Wolf et al; licensee BioMed Central Ltd.</copyright-statement><copyright-year>2014</copyright-year><copyright-holder>Wolf et al; licensee BioMed Central Ltd.</copyright-holder><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/4.0"><license-p>This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0">http://creativecommons.org/licenses/by/4.0</ext-link>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The Creative Commons Public Domain Dedication waiver (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/publicdomain/zero/1.0/">http://creativecommons.org/publicdomain/zero/1.0/</ext-link>) applies to the data made available in this article, unless otherwise stated.</license-p></license></permissions><self-uri xlink:href="http://www.cancerimagingjournal.com/content/14/S1/S3"/><conference><conf-date>9-11 October 2014</conf-date><conf-name>International Cancer Imaging Society (ICIS) 14th Annual Teaching Course</conf-name><conf-loc>Heidelberg, Germany</conf-loc></conference></article-meta></front><body><sec><title>Purpose</title><p>Purpose of this prospective, multi-institutional Phase I clinical study was to investigate whether MRI-guided transurethral ultrasound ablation (MR-TULSA), a novel minimally-invasive technology to treat organ-confined prostate cancer (PCa), is safe, feasible and effective. It employs directional plane-wave high-intensity ultrasound, which ablates prostate tissue using real-time thermometry with active temperature feedback control.</p></sec><sec sec-type="methods"><title>Methods</title><p>Enrolled were 30 patients with biopsy-proven, low-risk prostate cancer (age &#x02265; 65y, T1c/T2a, PSA &#x02264; 10ng/ml, Gleason 6 (3+3)). Whole-gland prostate ablation was performed with MR-TULSA using the PAD-105 (Profound Medical Inc., Canada) and a 3T MRI (Siemens, Germany) in one single treatment session under general anaesthesia and 3D active MR-thermometry feedback control. Contrast-enhanced MRI (CE-MRI) immediately following the ablation and at 12 months confirmed thermal coagulation.</p></sec><sec sec-type="results"><title>Results</title><p>There were no intraoperative complications with normal micturition resuming after catheter removal. Median (range) treatment time and prostate volume were 36 (24&#x02013;61) min and 44 (21&#x02013; 95) ml, respectively. Maximum temperature during treatment depicted a continuous region of heating shaped accurately to the prostate within 0.1 &#x000b1; 1.3 mm, with average over- and under- targeted volumes of 0.8 and 1.0 ml, respectively. Regions of acute cell kill on CE-MRI correlated well with treated volume on MR-thermometry. Successful treatment was further confirmed by a median PSA decrease from 5.35 to 0.70 ng/ml at 1 month (n=29), remaining stable to 0.65 ng/ml at 6 months (n=16).</p></sec><sec sec-type="conclusions"><title>Conclusion</title><p>Phase I results show that MR-TULSA represents a minimally-invasive treatment option for safe, effective and accurate whole-gland thermal ablation of organ-confined prostate cancer.</p></sec></body></article>